Carboxylate derivatives of tributyltin (IV) complexes as anticancer and antileishmanial agents

Carboxylate
DOI: 10.1186/s40199-017-0174-0 Publication Date: 2017-04-05T02:29:37Z
ABSTRACT
Tributyltin (IV) compounds are promising candidates for drug development. In the current study, we evaluated in-vitro and in-silico profile of carboxylate derivatives tributyltin complexes.ADMET drug-likeliness properties were predicted using MetaPrint2D React, preADMET, SwissADME Molsoft tools. SwissTargetPrediction molecular targets compounds. In-vitro bioactivity was by quantifying cytotoxicity against HepG2, THP-1 cell lines, isolated lymphocytes leishmania promastigotes as well measuring protein kinase (PK) inhibition activity.Results indicate partial compliance with rules. Ch-409 complies WDI Lipinski ADMET prediction shows strong plasma binding except Ch-409, low to high GI absorption BBB penetration (Cbrain/Cblood = 0.942-11; caco-2 cells permeability 20.13-26.75 nm/sec), potential efflux P-glycoprotein, metabolism CYP3A4, medium hERG, mutagenicity capacity be detoxified glutathionation glucuronidation. Molecular include proteases, enzymes, membrane receptors, transporters ion channels where receptors only. Compounds significantly (p < 0.05) cytotoxic HepG2 line compared normal lymphocytes. Ch-459 indicates highest toxicity (mortality 97.9 ± 3.99%; LC50 0.323 0.002 μg/mL) whereas possesses maximum (IC50 0.08 0.001 97.5 1.98% (LC50 0.954 0.158 mortality promastigotes. It observed that antileishmanial effect reduced 16.38%-34.38% 15-38.2% in presence NaN3 mannitol respectively. PK reactive oxygen species production possible mechanisms cytotoxicity.Selected complexes possess significant potential. These development anticancer drugs. Graphical Abstract Carboxylate agents.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (53)
CITATIONS (31)